Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.

ABSTRACT:

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) are increasingly recommended in type 2 diabetes. Hypoglycemia is a serious adverse effect of glucose-lowering agents. Real-world comparison of hypoglycemic risks among SGLT2i, GLP1RA, dipeptidyl peptidase-4 inhibitor (DPP4i), and sulfonylureas is limited.

Objective

Quantify the risk of hypoglycemia associated with SGLT2i, GLP1RA, DPP4i, and sulfonylureas (the primary reference group).

Design

Retrospective cohort study conducted using electronic health records from Geisinger Health, Pennsylvania (2015-2019).

Participants

A total of 10,713 patients with type 2 diabetes who newly received SGLT2i (n=1487), GLP1RA (n=1241), DPP4i (n=2938), or sulfonyl

SUBMITTER: Lyu B 

PROVIDER: S-EPMC9849518 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature